Search

Author/Creator Rubin, Mark S.

1. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). (November 2017)

Authors:
Spigel, David R.; Rubin, Mark S.; Gian, Victor G.; Shipley, Dianna L.; Burris, Howard A.; Kosloff, Rebecca A.; Shih, Kent C.; Quinn, Raven; Greco, F. Anthony; Hainsworth, John D.
Journal:
Lung cancer
Issue:
Volume 113(2017)
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search